Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab
- PMID: 34035954
- PMCID: PMC8135016
- DOI: 10.15420/cfr.2020.33
Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab
Abstract
Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses - in particular, the Coxsackie B viruses - are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.
Keywords: Devic’s syndrome; enterovirus; myocarditis; rituximab.
Copyright © 2021, Radcliffe Cardiology.
Conflict of interest statement
Disclosure: The authors have no conflicts of interest to declare.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources